---
schema_version: "secwatch.filing_event.v1"
accession: "0001104659-26-010345"
form_type: "8-K"
ticker: "PAHC"
cik: "0001069899"
company_name: "PHIBRO ANIMAL HEALTH CORP"
filed_at: "2026-02-04T23:59:59+00:00"
generated_at: "2026-05-16T04:48:05.514268+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Phibro Q2 net sales up 21% to $374M; raises FY2026 guidance

## Summary
- Net sales $373.9M (+21% YoY); net income $27.5M vs $3.2M; diluted EPS $0.67 vs $0.08.
- Adjusted diluted EPS $0.87 (+58% YoY); adjusted EBITDA $68.1M (+41% YoY).
- Animal Health sales +26% to $290M, driven by $57.5M incremental MFA portfolio revenue.
- FY2026 guidance raised: net sales $1.45-1.50B, adjusted EBITDA $245-255M, adjusted EPS $2.93-3.10.
- Gross margin improved 260 bps to 35.5%; 3.1x gross leverage ratio; free cash flow $47.3M TTM.

## SEC filing metadata
- accession: 0001104659-26-010345
- form_type: 8-K
- ticker: PAHC
- cik: 0001069899
- company_name: PHIBRO ANIMAL HEALTH CORP
- filed_at: 2026-02-04T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1069899/000110465926010345/0001104659-26-010345-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1069899/000110465926010345/pahc-20260204x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001104659-26-010345
- JSON: https://secwatch.observer/filing/0001104659-26-010345.json
- Plain text: https://secwatch.observer/filing/0001104659-26-010345.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.